Answers are grounded in this paper and cite their sources.
In this retrospective multicenter study, the presence of the BRAF V600E mutation was significantly associated with increased cancer-related mortality among patients with PTC. Because overall mortality in PTC is low and the association was not independent of tumor features, how to use BRAF V600E to manage mortality risk in patients with PTC is unclear. These findings support further investigation of the prognostic and therapeutic implications of BRAF V600E status in PTC.
No takes yet. Share an insight, caveat, or question.
Xing et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: